Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will also finance move to new laboratory facilities in the Illkirch-Graffenstaden innovation park in northeast France
April 18, 2017
By: Tim Wright
Editor-in-Chief, Contract Pharma
Inoviem Scientific, a contract research biotech (CRB), has secured funding of $693k from Cap Innov’Est, the French public investment bank Bpifrance and its own banks, as well as a $107k grant from Strasbourg Eurométropole. Inoviem has already received funding of more than $1.07 million in 2015, from Cap Innov’Est and Bpifrance. With this new financing, the company has already invested part of the funding in fitting out six laboratories to expand and enhance the range of services offered. After receiving the ISO 9000:2015 certification in September 2016, Inoviem moved to the Bioparc 3 building on the Illkirch-Graffenstaden innovation park, south of Strasbourg, France. The new laboratory facilities have a surface area of 560 square meters, which is five times larger than its former premises. Inoviem Scientific supplies pharmaceutical companies with key information on drug-target interaction to support decision-making along the value chain from drug discovery to post-marketing, including the pre-clinical and clinical stages of development. Today, one of the main barriers in drug discovery and development is its high attrition rate, largely due to a lack of efficacy and unexpected side effects. While conventional technologies fail to take into account the natural environment in which molecular interactions occur, Inoviem’s approach is to reconnect technical analysis with physiological complexity. To meet this challenge the company offers their label free technologies, NPOT and PIMS, working on human tissue in clinical conditions. “The confidence our partners have shown in our plans represents a real development opportunity for Inoviem Scientific. Our business continues to grow and we plan soon to hire four new staff members,” said Pierre Eftekhari, president and founder of Inoviem Scientific. “Inoviem is dedicated to predicting mechanism of action, efficacy and toxicity, and performing biomarker identification, to better manage the risks and speed up the development of compounds with benefits for public health.” Frédéric Perraud, chief financial officer, Inoviem Scientific, said, “We have seen our revenue increase sharply. The first few months of 2017 confirmed this trend. Moving premises was vital to supporting our business growth and broadening our range of services while maintaining the high level of quality. Our expertise and powerful technology have already helped us win the loyalty of our customers.” Inoviem Scientific also plans to allocate a part of the funding to developing its sales activities outside Europe. In addition, the company will offer a new range of services related to the NPOT technology.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !